![](/img/cover-not-exists.png)
A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression
Warren P. Mason, Karl Belanger, Garth Nicholas, Isabelle Vallières, David Mathieu, Petr Kavan, Annick Desjardins, Antonio Omuro, Didier ReymondVolume:
107
Language:
english
Pages:
7
DOI:
10.1007/s11060-011-0747-6
Date:
April, 2012
File:
PDF, 310 KB
english, 2012